EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Readiness quiz

What should your team do next?

Dose Diligence research deskSection 08 · Page 20 of 22Last updated 17 Nov 2026

Turn the result into a short action register. Work in this order: blocking issues, missing gate evidence, launch-critical operating controls, then economic and service improvements.

Lowest-scoring areaSuggested work productAccountable lead
Q1: spending and decision authorityOperating-model and money-flow mapCFO and COO
Q2: route eligibilityBefore-You-Sign Supply-Route ScreenCounsel and medical director
Q3–4: state coverage and supplier evidenceState-Expansion Gap Map and Supplier Evidence AuditCompliance and procurement
Q5: handling and safetyProduct-specific procedures and simulationMedical director and pharmacy lead
Q6–8: route and economicsBranded Access Workflow Comparator and True-Cost CalculatorOperations and finance
Q9–11: capacity and continuityService-level schedule and Failure Stress TestCOO
Q12: patient informationData-flow and security reviewPrivacy/security lead
Q13: commitments and exitContract Exposure RegisterCounsel and CFO
Q14–15: implementation and governanceTransition playbook and approval recordCOO and executive sponsor

These are suggested deliverables, not prerequisites to purchasing a research service. An internal team can prepare them, with specialist support where needed.

What should the completed result contain?

Use this copyable record:

  • Arrangement assessed: product, presentation, entity, facility, operating model and states.
  • Decision: new appointment / renewal / replacement / expansion.
  • Decision date and owner: ______.
  • Question scores: Q1 ___; Q2 ___; Q3 ___; Q4 ___; Q5 ___; Q6 ___; Q7 ___; Q8 ___; Q9 ___; Q10 ___; Q11 ___; Q12 ___; Q13 ___; Q14 ___; Q15 ___.
  • Total: ___ / 45.
  • Gate status: satisfied for assessed scope / evidence hold.
  • Blocking issues: ______.
  • Three priority actions: each with an owner, evidence requirement and completion date.
  • Scope exclusions: states, products, facilities or workflows not approved for activation.
  • Next review: date and event triggers.

The useful outcome is not the number. It is a defensible explanation of what you can decide now, what remains unknown and who must resolve it.

Explore the table row by row

A working view of the research

Q1: spending and decision authority

Suggested work product
Operating-model and money-flow map
Accountable lead
CFO and COO

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →